Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | BRD4 | O60885 | 3/20 | 0.42 |
| ▸ | EDNRB | P24530 | 4/20 | 0.40 |
| ▸ | EDNRA | P25101 | 4/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8185278 | 0.85 | EDNRB (0.43) | NPC1RAB9ABRD4EDNRBEDNRA | |
| SCHEMBL7214959 | 0.84 | BRD4 (0.38) | BRD4GRM4CYP1A2CHRNB2CHRNA4 | |
| SCHEMBL8203287 | 0.81 | GABRA1 (0.42) | BRD4EDNRBEDNRAGRM4CYP1A2 | |
| SCHEMBL13201416 | 0.80 | TRPA1 (0.47) | NPC1RAB9ATRPA1ALDH1A1HTT | |
| SCHEMBL12044601 | 0.80 | RAB9A (0.41) | NPC1RAB9ATRPA1ALDH1A1HTT | |
| SCHEMBL13181801 | 0.80 | GRM4 (0.40) | NPC1RAB9ABRD4GRM4CYP1A2 | |
| SCHEMBL21257487 | 0.79 | CSNK2A2 (0.41) | NPC1RAB9ATRPA1ALDH1A1SMN1; SMN2 | |
| SCHEMBL10083311 | 0.78 | MAPT (0.56) | NPC1RAB9AALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL22419386 | 0.77 | RAB9A (0.38) | NPC1RAB9ATRPA1GRM4CYP1A2 | |
| SCHEMBL5985206 | 0.76 | MAPT (0.53) | NPC1RAB9ABRD4GRM4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10457667-B2 | Indolin-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20100249102-A1 | Heterotricyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDINGS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7749996-B2 | Heterotricyclic metalloprotease inhibitors | Alantos Pharmaceutical Holdings, Inc. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20100087420-A1 | Heterotricyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDINGS, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-7691902-B2 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); amido-phenyl derivatives; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis and lipid processing deficiencies, lysosomal storage disease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-06 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20080221092-A1 | Heterobicyclic metalloprotease inhibitors | BLUHM HARALD | 2008-09-11 | — | — | US | disclosed |
| WO-2008063669-A1 | HETEROBICYCLIC MATRIX METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008063670-A1 | HETEROBICYCLIC MATRIX METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20080044355-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); amido-phenyl derivatives; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis and lipid processing deficiencies, lysosomal storage disease | VERTEX PHARMACEUTICALS INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| US-20080021024-A1 | Metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-01-24 | — | — | US | disclosed |
| WO-2008002671-A2 | METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-01-03 | — | — | WO | disclosed |
| WO-2007139860-A2 | HETEROBICYLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS, INC. (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007079199-A2 | SUBSTITUTED BIS-AMIDE METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS, HOLDING, INC. (US) | 2007-07-12 | — | — | WO | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155739-A1 | Substituted bis-amide metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155737-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155737-A1 | Heterobicyclic metalloprotease inhibitors | ADAMTS4, ADAMTS1, ADAMTS5 | NPC1 3130/4885RAB9A 2920/4885BRD4 167/4885 |
| US-10457667-B2 | Indolin-2-one derivatives | GRIN2B, GRIN2A, GRIN2D | NPC1 950/4885RAB9A 2076/4885BRD4 736/4885 |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | MMP13, TIMP3, MMP3 | NPC1 2374/4885RAB9A 1239/4885BRD4 421/4885 |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | MMP13, TIMP3, MMP3 | NPC1 2374/4885RAB9A 1239/4885BRD4 421/4885 |
| US-20100087420-A1 | Heterotricyclic Metalloprotease Inhibitors | MMP13, MMP3, TIMP3 | NPC1 2401/4885RAB9A 2487/4885BRD4 545/4885 |
| US-20080044355-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); amido-phenyl derivatives; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis and lipid processing deficiencies, lysosomal storage disease | CFTR, ABCB4, ABCF2 | NPC1 19/4885RAB9A 1088/4885BRD4 3868/4885 |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | NPC1 2374/4885RAB9A 1239/4885BRD4 421/4885 |
| US-20100249102-A1 | Heterotricyclic Metalloprotease Inhibitors | MMP13, MMP3, TIMP3 | NPC1 2401/4885RAB9A 2487/4885BRD4 545/4885 |
| US-20070155739-A1 | Substituted bis-amide metalloprotease inhibitors | MMP13, MMP9, ADAMTS13 | NPC1 2317/4885RAB9A 1295/4885BRD4 412/4885 |
| US-20080021024-A1 | Metalloprotease inhibitors | MMP2, MMP9, MMP3 | NPC1 1618/4885RAB9A 2689/4885BRD4 786/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | NPC1 2374/4885RAB9A 1239/4885BRD4 421/4885 |
| US-20080221092-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, MMP3, TIMP3 | NPC1 2548/4885RAB9A 1516/4885BRD4 373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.